Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06230185 · ClinicalTrials.gov registry record
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A clinical trial of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease, sponsored by Personalis.
- Recruiting
- Registry status
- 422
- Enrollment target
- 14
- Study locations
NCT06230185 is a study of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease that is actively recruiting participants, run by Personalis. The registered enrollment target is 422 participants, roughly in line with the 462-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target. The trial reports 14 study locations across 13 states.
The verdict
NCT06230185, a study of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease, is actively recruiting participants, sponsored by Personalis.
- RECRUITING
- Registry status
- 422 participants
- Enrollment target
- 14
- Study locations
Study Summary
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Conditions Studied
Study Locations (14)
Florida
- Mount Sinai Medical Center of Florida - Miami Beach
- Comprehensive Hematology Oncology (ONare Alliance, LLC / Exigent Research, LLC - St. Petersburg
Arizona
- Arizona Oncology - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- George Washington University - Washington D.C.
Illinois
- Illinois Cancer Care - Peoria
Louisiana
- Louisiana State University - New Orleans
Michigan
- Trinity Health-Michigan - Ypsilanti
Nebraska
- Nebraska Methodist - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06230185
The ClinicalTrials.gov registry entry for NCT06230185 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 462-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target. The listed sponsor is Personalis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with TNBC - Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06230185 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Florida, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06230185 about?
NCT06230185 is a clinical study titled "CtDNA Based MRD Testing for NAC Monitoring in TNBC". A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results ...
What is the current status of trial NCT06230185?
This trial is currently recruiting. The enrollment target is 422 participants. The study started on 2023-11-09. Estimated completion is 2025-12-31.
What conditions does trial NCT06230185 study?
This clinical trial studies the following conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease.
Who is sponsoring clinical trial NCT06230185?
This trial is sponsored by Personalis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06230185 being conducted?
This trial has 14 study locations across Arizona, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for TNBC - Triple-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.